Want to see ADIL full AI Analyst Report?
ADIL Stock Chart & Stats
$2.78
$0.10(3.73%)
At close: 4:00 PM EDT
$2.78
$0.10(3.73%)
Day’s Range― - ―
52-Week Range$1.31 - $10.76
Previous CloseN/A
Volume38.05K
Average Volume (3M)102.19K
Market Cap
$13.10M
Enterprise Value$45.46
Total Cash (Recent Filing)$28.71M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Nov 18, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.53
Shares Outstanding2,625,890
10 Day Avg. Volume29,103
30 Day Avg. Volume102,186
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.50Price Target Upside205.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt limits refinancing and interest-rate exposure, giving ADIL some financial flexibility while it develops its pipeline. This benefit is meaningful for a clinical-stage company, although it does not offset the broader balance-sheet weakness.
Pipeline FundingThe financing can extend development runway and support AT177 through early clinical milestones, reducing immediate dependence on additional funding. The merger also adds an inflammatory-disease program, broadening the company’s potential long-term pipeline.
Precision Medicine ModelCombining a targeted therapy with companion diagnostics could improve patient selection and support differentiated clinical development in alcohol use disorder. If validated, this model may strengthen trial efficiency and commercialization prospects versus broadly targeted treatments.
Bears Say
No RevenueADIL remains entirely pre-commercial, so it lacks product revenue to fund research, operations, or future trials. Continued dependence on capital markets and successful clinical development leaves the business exposed to funding constraints over the next several quarters.
Widening LossesThe sharp increase in losses indicates substantially higher spending without corresponding revenue progress. Unless development investment produces clinical or partnering milestones, this cost structure could accelerate dilution and pressure the company’s ability to sustain its pipeline.
Cash Burn And Negative EquityPersistent cash burn shows that operations are not self-funding, while deeply negative equity signals accumulated losses and capital-structure stress. Together, these conditions increase reliance on external financing and may restrict strategic flexibility during clinical execution.
Adial Pharmaceuticals News
ADIL FAQ
What was Adial Pharma’s price range in the past 12 months?
Adial Pharma lowest stock price was $1.31 and its highest was $10.76 in the past 12 months.
What is Adial Pharma’s market cap?
Adial Pharma’s market cap is $13.10M.
When is Adial Pharma’s upcoming earnings report date?
Adial Pharma’s upcoming earnings report date is Nov 18, 2026 which is in 91 days.
How were Adial Pharma’s earnings last quarter?
Adial Pharma released its earnings results on Aug 17, 2026. The company reported -$11.25 earnings per share for the quarter, missing the consensus estimate of -$1.032 by -$10.218.
Is Adial Pharma overvalued?
According to Wall Street analysts Adial Pharma’s price is currently Undervalued.
Does Adial Pharma pay dividends?
Adial Pharma does not currently pay dividends.
What is Adial Pharma’s EPS estimate?
Adial Pharma’s EPS estimate is -0.42.
How many shares outstanding does Adial Pharma have?
Adial Pharma has 2,625,890 shares outstanding.
What happened to Adial Pharma’s price movement after its last earnings report?
Adial Pharma reported an EPS of -$11.25 in its last earnings report, missing expectations of -$1.032. Following the earnings report the stock price went up 25.377%.
Which hedge fund is a major shareholder of Adial Pharma?
Currently, no hedge funds are holding shares in ADIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adial Pharma
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
ADIL Stock 12 Month Forecast
Average Price Target
$8.50
▲(205.76% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Alzamend Neuro
―
Calidi Biotherapeutics
―
Ownership Overview
30.11% Insiders
0.24% Mutual Funds
28.84% Other Institutional Investors
40.59% Public Companies and
Individual Investors